Zoonotic & Vector-Borne Diseases

Researchers identify Camp Hill virus, a novel henipavirus in shrews, raising concerns about human exposure to emerging infectious diseases.

Oropouche fever, primarily found in Central and South America and the Caribbean, has seen a dramatic increase in cases in Brazil.

Caryn Fenner and Petro Terblanche outline Afrigen's clinical trial plans, local partnerships, and vaccine pipeline.

These types of infections will continue to rise, and there is a need to understand what we are witnessing and find ways to combat them.

Rising temperatures and changing humidity are undermining natural pest control, putting North American forests at risk.

Over a third of respondents in 6 African countries were hesitant to get the vaccine themselves. And for parents, nearly 40% were reluctant to get their children immunized.

The largest blastomycosis outbreak linked to a paper mill in Michigan and a 56% increase in tularemia cases over the past decade.

Emerging data reveal surprising patterns in maternal–fetal outcomes linked to avian influenza virus infection.

143 deaths and 592 cases confirmed in Kwango Province, with concerns about treatment access, drug resistance, and more.

Health officials are investigating an outbreak called "Dinga Dinga," which causes fever and uncontrollable shaking.

Sexual transmission was confirmed for nine of the 22 viruses studied, including Ebola, Zika, and mpox, making it a key factor in ongoing disease spread.

Milad Zandi, PhD, on rising temperatures and the spread of mosquito-borne diseases like dengue, Zika, and chikungunya, increasing the risk of outbreaks in tropical and temperate regions.

This comes after Japan recently announced it will donate over 3 million doses of the mpox vaccine, LC16m8 to a country in Africa.

The person had recently traveled to areas experiencing clade I mpox virus transmission and sought medical care for mpox symptoms in the United States.

A new study confirms the growing belief and evidence this vector-borne diseases will increase and see a greater burden globally.

With up to 37.5% of children carrying this resistance mutation the findings suggest that current treatment protocols may be losing effectiveness.

The pharmaceutical company said there were no safety issues associated with the decision.

With 26 cases confirmed and several fatalities, the African country is experiencing its first bout of the zoonotic disease.

The susceptibility of mosquito larvae and pupae to infection via excreta, emphasizes the potential for increased virus persistence within mosquito populations.

The federal agency offers guidance for US clinicians and travelers to understand the disease better and employ preventative measures to reduce incidence rates.

A new survey reveals that infectious disease virologists, epidemiologists and clinicians see the need to address gaps in surveillance programs to identify emerging pathogens, public health funding and testing infrastructure capabilities.

With no vaccines or specific treatments available, the mosquito-borne pathogen, which causes fever, severe headache, and joint pain, raises alarms due to its spread across the Americas.

The organization's designation for the Bavarian Nordic’s MVA-BN (Jynneos) mpox vaccine is aimed at helping with the public health response, especially in Africa, where incidences rates continue to increase.

Jennifer Ronholm, PhD, discusses the novel concept of microbiome protection to create healthier animals and reduce antimicrobial usage.

The town of Plymouth decided to prohibit people from using the parks from dusk to dawn due to concerns over eastern equine encephalitis after a man contracted the rare disease in the state.

Transmission to humans is limited in the US, but concerns linger, especially in the wake of the COVID-19 pandemic.

The study found that the vaccine, combined with presumptive antimalarial treatment, reduced Plasmodium falciparum parasitaemia and clinical malaria over two transmission seasons.

Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.

We have complied some of our news stories and interviews from the last week to offer information on the differences between clade I and clade 2 mpox, why WHO declaring the global emergency is significant, looking at mpox in the United States, and more.

The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.